330 related articles for article (PubMed ID: 24522741)
21. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
Chow R; Chiu L; Herrstedt J; Aapro M; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Aug; 29(8):4269-4275. PubMed ID: 33409724
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced nausea and vomiting.
Lohr L
Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
Filetti M; Lombardi P; Giusti R; Falcone R; Scotte F; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Cancer Treat Rev; 2023 Apr; 115():102512. PubMed ID: 36774658
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
[TBL] [Abstract][Full Text] [Related]
26. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
[TBL] [Abstract][Full Text] [Related]
27. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.
van der Vorst MJ; Neefjes EC; Konings IR; Verheul HM
Support Care Cancer; 2015 Aug; 23(8):2499-506. PubMed ID: 26041480
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Osman AAM; Elhassan MMA; AbdElrahim BHA; Ahmed FHA; Yousif JBH; Ahmed MAM; Abdelhafeez RHA; Ahmed UMY
J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241275
[TBL] [Abstract][Full Text] [Related]
30. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
Vig S; Seibert L; Green MR
J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
[TBL] [Abstract][Full Text] [Related]
32. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Park SH; Binder G; Corman S; Botteman M
J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
[No Abstract] [Full Text] [Related]
33. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
[TBL] [Abstract][Full Text] [Related]
34. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.
Liu J; Tan L; Zhang H; Li H; Liu X; Yan Z; Chen J; Yang H; Zhang D
Eur J Cancer Care (Engl); 2015 May; 24(3):436-43. PubMed ID: 25404537
[TBL] [Abstract][Full Text] [Related]
35. Palonosetron: in the prevention of nausea and vomiting.
Yang LP; Scott LJ
Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
38. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.
Mukhopadhyay S; Kwatra G; Alice K P; Badyal D
Support Care Cancer; 2017 Jan; 25(1):145-154. PubMed ID: 27591991
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Boccia R; O'Boyle E; Cooper W
BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
